Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

  • the DAPA-CKD Trial Committees and Investigators

Background Dapagliflozin reduces kidney failure risk in patients with CKD but can result in a reversible acute reduction in eGFR upon treatment initiation. Determinants of this eGFR reduction and its associations with efficacy and safety outcomes are unknown. Methods The DAPA-CKD trial randomized 4304 adults with CKD and albuminuria to once-daily dapagliflozin 10 mg or placebo, added to standard care. We prespecified an analysis comparing the effects of dapagliflozin among patients who experienced relative reductions in eGFR (>10% or >0%-10%) or an increase in eGFR from baseline to 2 weeks and assessed long-term efficacy and safety thereafter. Results A total of 4157 (96.6%) patients had eGFR data available at baseline and at 2 weeks. In the dapagliflozin and placebo groups, 1026 (49.4%) and 494 (23.7%), respectively, experienced an acute reduction in eGFR >10%. Among patients receiving dapagliflozin, those with an acute reduction in eGFR >10% experienced a long-term eGFR decline of -1.58 ml/min per 1.73 m2 per year compared with -2.44 and -2.48 ml/min per 1.73 m2 per year among those experiencing a less pronounced reduction or increase in eGFR, respectively (P-interaction=0.05). In the placebo group, long-term eGFR decline was -3.27, -3.84, and -3.77 ml/min per 1.73 m2 per year for acute eGFR reduction subgroups of >10%, >0%-10%, or increase in eGFR (P-interaction=0.48). Rates of serious adverse events and adverse events of special interest in patients randomized to dapagliflozin were unrelated to the acute eGFR change. Conclusions Among patients with CKD and albuminuria treated with dapagliflozin, an acute reduction in eGFR (from baseline to 2 weeks) is not associated with higher rates of CKD progression. Clinical Trial registration number: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD) NCT03036150.

OriginalsprogEngelsk
TidsskriftJournal of the American Society of Nephrology
Vol/bind33
Udgave nummer11
Sider (fra-til)2094-2107
Antal sider14
ISSN1046-6673
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
The authors thank all investigators, trial teams, and patients for their participation in the trial. The authors would also like to acknowledge Parita Sheth, inScience Communications, London, UK, for assistance in editing and preparation of figures. H. Heerspink is supported by the BEAt-DKD project. The BEAt-DKD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 115974. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. R. Toto’s contribution to this manuscript was supported by endowments from the Mary M. Conroy Professorship in Kidney Disease and the Houston J. and Florence A. Doswell Center for the Development of New Approaches for the Treatment of Hypertension.

Funding Information:
The DAPA-CKD study was funded by AstraZeneca.

Funding Information:
The DAPA-CKD study was funded by AstraZeneca. The authors thank all investigators, trial teams, and patients for their participation in the trial. The authors would also like to acknowledge Parita Sheth, inScience Communications, London, UK, for assistance in editing and preparation of figures. H. Heerspink is supported by the BEAt-DKD project. The BEAt-DKD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement 115974. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations. R. Toto's contribution to this manuscript was supported by endowments from the Mary M. Conroy Professorship in Kidney Disease and the Houston J. and Florence A. Doswell Center for the Development of New Approaches for the Treatment of Hypertension.

Publisher Copyright:
Copyright © 2022 by the American Society of Nephrology.

Links

ID: 330396002